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Background: To quantify the contribution of locally implemented prevention programmes in contributing to
reductions in treatment and care costs by averting HIV infections among those who inject drugs this study
calculates net financial benefit of providing harm reduction programmes using information from services being
implemented in Urumqi, Xinjiang Uighur Autonomous Region of China ( between 2005 and 2010).
Methods: Information was collected to assess cost of providing methadone treatment (MMT) and needle and
syringe programmes (NSP). HIV incidence was estimated among people who inject drugs (PWID). HIV infections
averted were calculated. Net benefit was assessed by estimating costs of providing prevention programmes and
comparing these to the costs of providing care.
Results: An estimated 5678 (range 3982–7599) HIV infections were averted between 2005 and 2010 and the net
financial benefit of providing harm reduction programmes compared to treatment and care costs for HIV infections
averted was USD 4.383 million during the same time period.
Conclusion: These results demonstrate the net and accumulating benefit of investing in harm reduction
programmes for PWID in Urumqi. The return on investment progressively increased during the time period studied
and it is clear that these cost savings will continue to accrue with the continued implementation of HIV prevention
interventions in the community that include harm reduction programmes targeted at PWID.
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Over the last several years increasing numbers of studies
have sought to demonstrate positive benefits of prevent-
ing transmission of blood borne infections including
HIV through implementation of harm reduction pro-
grammes for people who inject drugs (PWID). In 2001,
a country wide analysis was carried out in Australia to
project a return on investment of implementing needle
and syringe programmes (NSP) in preventing transmis-
sion of HIV and Hepatitis C [1]. Subsequent small and
large scale studies undertaken in a variety of settings
have all shown positive health outcomes and signi-
ficant cost savings as has a 2009 follow-up study in* Correspondence: kimwheel@yahoo.com
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reproduction in any medium, provided the orAustralia [2]. Methadone maintenance therapy (MMT)
programmes have also been evaluated for their impact
on preventing HIV transmission and reducing crime
rates [3,4]. However there are very few studies arising
from China examining the financial benefits of com-
bined harm reduction programmes (NSP and MMT)
for PWID.
HIV among PWID was first identified in China in
1989. Since that time more than 370,000 people have
been identified as living with HIV. Injecting drug use
remains a common transmission route particularly in
Yunnan province and Guangxi Zhang and Xinjiang
Uighur Autonomous Regions.
The Xinjiang Uighur Autonomous Region (XUAR), in
the northwest of the People’s Republic of China, ranks
fifth in HIV prevalence in China. Between 1996 and the
end of December 2010 33,149 people in the region hadThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of people with HIV in China) (People’s Republic of
China National HIV and AIDS Case Reporting 2010). Of
these PLHIV, 54.7% reported having injected drugs.
In XUAR, high rates of sharing injecting equipment
have been found in the absence of harm reduction pro-
grammes. In 2001, research in 20 counties and cities in
XUAR showed that 69.5% of drug users had injected
drugs and 61.2% of them reported sharing injecting
equipment. The rate of sharing in some specific regions
such as Yining City was as high as 83.9%. Operational
research in 2006 to evaluate the impact of harm reduc-
tion programmes funded by the China-Australia
Xinjiang HIV/AIDS Prevention and Care Project (XJHA-
PAC) showed that between 50-70% of people who
injected drugs reported having shared needles and
syringes. At the end of 2008 those rates had dropped to
20-40%.
Harm reduction programmes began in XUAR in 2004
with a pilot NSP in Yining City (an area in the north of
XUAR significantly affected by HIV amongst PWID).
The programme was expanded in 2006 to Urumqi (cap-
ital city of XUAR) and Kashgar City (southern XUAR)
and subsequently to many areas of XUAR known to
have high numbers of PWID. These interventions were
initially financed by international donor funds and, from
2009 onwards, by national and local government
funding.
MMT began in XUAR in Yining, Urumqi and Kashgar
Cities in 2005 and since that time have been expanded
into many areas of XUAR. The national government
funded the establishment of the initial clinics and MMT
continues to be funded through national and local gov-
ernment contributions.
This paper explores the net financial benefit in
Urumqi of providing harm reduction programmes in
averting HIV infection as a consequence of injecting
drug use as compared to the costs of providing HIV
treatment and care. Urumqi was chosen as the site for
this research based on completeness of records and
readiness of access to staff. This study draws on available
information about the incidence of HIV among PWID
between 2000 and 2010 and specific studies to assess
costs.
Methods
Numbers of community based service users were col-
lected from existing reporting systems for NSP sites and
MMT clinics in Shuimogou, Shayibake and Tianshan
Districts of Urumqi. The costs of implementing harm
reduction programmes were collected from financial
records and a survey of staff from these same sites. The
survey collected information for 2008–2010 for MMT
and 2006–2009 for NSP.Costs were assessed based on establishment costs
(equipment, staff training), operational fixed costs (rent,
utilities, equipment maintenance, staff salaries) and op-
erational variable costs (in-service staff training and con-
sumables for testing; supplies such as methadone,
needles and syringes and condoms). These cost defini-
tions are generally accepted as describing direct costs of
services [5]. Income from national and local govern-
ment, donor and service user payments covered the
costs of providing MMT services.
Costs for MMT were estimated for 2006 and 2007
based on cost per service user derived from the 2008
costs. Costs for NSP in 2010 were estimated based on
costs per service user in 2009.
Trends in incidence were measured by BED HIV-1
EIA Assay testing. Blood samples were tested from drug
users resident at the Urumqi City Public Security Bureau
Detoxification Centre from 2000 to 2010. From 2000–
2005, BED HIV-1 EIA Assay testing was carried out on
stored blood samples and from 2006–2010 on fresh
samples. Obtaining blood samples from all residents in
Detoxification Centers is a routine component of admis-
sion and required for the regional surveillance system.
Residents were informed of the reasons for blood sam-
pling. Informed consent for the use of stored blood sam-
ples was not possible to obtain due to the lack of
accurate and current contact information for those who
had given samples between 2000 and 2005.
To estimate PWID community based population size,
study results from previous internal studies were used.
In 2010, an internal XUAR Centre for Disease Control
research study showed that 68.2% of 2487 drug users in
various communities including Urumqi, reported having
injected opiates. Therefore, the population size of PWID
was estimated based on numbers of registered (10,481)
and estimated total drug users (20,000) in Urumqi pro-
vided by the XUAR Public Security Bureau. The mini-
mum number of registered PWID was 7,148 (68.2% of
10,481) and the maximum number was 13,640 (68.2% of
20,000). These estimates were used to establish the
upper and lower ranges for HIV infections averted in
each year of the study.
To estimate HIV infections averted incidence was pro-
jected for 2006 to 2010 based on the average rate of in-
crease as measured in samples between 2000 and 2005
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actual results on tested blood between 2005 and 2010
and the difference between these results enabled estima-
tions of infections averted.
Costs of providing treatment and care were calculated
based on personal costs for PLHIV and government sup-
ported costs. Personal costs for PLHIV were estimated
from survey results of 100 PLHIV in Urumqi (36 partici-
pants were using antiretroviral therapy (ART) and 64
were not). Government costs were summated based on
testing costs, provision of ART, treatment costs of op-
portunistic infection and follow-up service delivery. The
government supported costs for providing free treatment
and other services were added to the personal costs to
derive the total direct costs of treatment.
Calculation of annual and cumulative net benefit was
based on annual costs of providing harm reduction pro-
grammes which were derived from the average costs of
treatment services. This provided the basis for the deriv-
ation of estimated net financial benefit and a ratio of
comparative investment (USD1 spent on harm reduction
saves USDX spent on treatment).
All data were input to EpiData (Version 3.1) and ana-
lysis was completed with SPSS (Version 11.0). All infor-
mation used in this paper was provided by the Xinjiang
Uighur Autonomous Regional Center for Disease Con-
trol. Information ascertained through surveys was pro-
vided freely and openly by survey participants.
The XUAR Bureau of Health Ethics Committee was
established to support the implementation of the China
National Bureau of Health Research Programme. The in-
formation collection and methodologies used to support
this study were approved by this group.
Results
Service users
The number of users of harm reduction services is given
in Table 1. These figures capture the number of people
who used NSP services at least four times during a year
or continued to use MMT services throughout a year.
For the purpose of this study it has been assumed that
all service users have an opportunity to learn basic infor-
mation about HIV and repeated service contact indicates
intention to change risk behaviors.
The numbers of users of services increased annually
over the time period studied from 2320 in 2006 to 3867Table 1 Numbers of people who inject drugs using harm
reduction services
2006 2007 2008 2009 2010
Methadone maintenance therapy (MMT) 1407 2430 2569 2111 1852
Needle and syringe programmes (NSP) 913 1303 1298 1669 1556
Total 2320 3733 3867 3780 3408in 2008, declining to 3408 in 2010. A variety of reasons,
including funding changes and social issues, account for
the 11.8% decline in service user numbers between 2008
and 2010 . Reductions in funding for the NSP changed
the arrangement of outreach service provision and at
many sites outreach worker numbers were reduced and
linked to MMT. Social unrest in Urumqi in 2009 and
subsequent increased police activity also reduced the
numbers of contactable PWID in the community.Costs of harm reduction programmes
Costs of NSP were collected from sites for 2006–2009
and 2010 costs were estimated based on costs per ser-
vice user in 2009. Significant variation in financial input
to NSP is due to large injections of funding from XJHA-
PAC to establish NSP sites in 2006 and to expand ser-
vices and coverage in 2008. The Global Fund also
supported activities over that period (2006–2008). It is
therefore assumed that the financial inputs in 2009,
when both of these external funding sources stopped,
are more closely aligned with actual current costs of op-
eration of NSP sites. Therefore, the 2010 costs per ser-
vice user were assessed based on 2009 costs per service
user of 470.28 RMB (USD72) (Table 2).
Costs of providing MMT were collected by survey at
participating sites for 2008–2010. Costs for 2006 and
2007 were estimated based on costs per service user in
2008 (Table 2). Average cost per year was USD641,532
with costs being highest in 2008 when investment in
both services was USD812,922 to facilitate expansion of
services.Estimating HIV infections averted
HIV incidence among PWID
BED HIV-1 EIA Assay testing was carried out on sam-
ples collected as part of the national sentinel surveil-
lance. Between 2000 and 2010 14,524 blood samples
from people who inject drugs were tested. Of these 4740
were found HIV positive, 2628 were included in BED
HIV-1 EIA Assay (after exclusion of duplicate samples
and those already in the case reporting system) and 504
new cases of infection were confirmed. Annual HIV inci-
dence (based on the China correction coefficient) was
determined (Figure 1). From 2000 to 2005, (pre-service
period) 62.2% of the blood samples in the series were
analysed and from 2006 onwards the remaining 37.8%
were included in the analysis.
The incidence trends indicated that, between 2000 and
2004, incidence increased gradually (8.37% to 12.49%)
and from 2005 onwards, incidence declined from
12.42%, to 8.03% in 2006 and 4.63% in 2010 (Figure 1).
The most significant decline in incidence appears to be
from 2005 to 2008 which also correlates with an increase
Table 2 Estimated costs of harm reduction services in Urumqi
2006 2007 2008 2009 2010
Total cost of MMT (RMB) 1,715,133* 2,962,170* 3,131,538 3,429,569 3,217,224
Total cost of NSP (RMB) 1,697,101 1,027,948 2,152,454 784,905 731,756*
Total (RMB) 3,412,234 3,990,118 5,283,992 4,214,474 3,948,980
Total (USD)** $524,959 $613,864 $812,922 $648,381 $607,535
* Estimated costs **USD1 = 6.5RMB.
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(Table 1).
It should be noted that sample size, after correction, in
2008 (627), 2009 (1022) and 2010 (303) was significantly
lower than other years (where sample size ranged be-
tween 1100 and 1800 per year) due to pressures of work
for the Center for Disease Control (CDC). However, it
appears that the whole series tends to show a decline in
incidence from 2005 (Figure 1).
Harm reduction programmes were introduced in
Urumqi in 2005 and augmented from 2006 onwards by
continuous community-based HIV prevention promo-
tion activities and outreach services. On this basis it is
concluded that the programmes included in this study,
being the only services of this type in Urumqi, have, in
part, contributed to reducing incidence of HIV among
PWID.
HIV infections averted
Using the difference between projected incidence and
BED HIV-1 EIA estimated incidence it was then possible
to derive the number of HIV infections averted (Table 3).
Average HIV infections averted between 2005 and 2010
are estimated to be 5790 (range 3982–7599).
In calculating these figures the number of PWID is
assumed to be static. In addition, the progression of HIV
in the drug using group in the absence of prevention
services is assumed to increase at the same rate as the
population being tested. However, identification of HIV









































Figure 1 Incidence of HIV among PWID.accurate case reporting which may mean that the pro-
gression of disease within the entire injecting drug using
population cannot be clearly defined or projected at any
specific time.
Costs of providing treatment and care
The personal financial costs of being HIV positive were
assessed by survey and these were added to the direct
costs supported by government for those diagnosed but
not on antiretroviral therapy (ART) and those people liv-
ing with HIV (PLHIV) on ART. The average cost was
found to be USD386.30 per year for those not on treat-
ment and USD1147.20 for those on ART.
The results of survival information from within China
and internationally were used to estimate annual average
costs of treatment and care for the two treatment sce-
narios. Survival with untreated HIV is 9–11 years and
diagnosis usually occurs within 2–5 years [7]. According
to information from surveys within China, 76% of
PLHIV survive at least 5 years on ART [8]. In some
developed countries survival can be extended up to
50 years (average 29 years) [9].
In China, free ART was first introduced in 2004 for
those with CD4 ≤ 200. From 2010 onwards the national
free treatment scheme was provided for people with
CD4 ≤ 350. From 2010, in some selected regions, includ-
ing XUAR, free treatment was provided from diagnosis
for those with CD4 between 350 and 500 (on average
two years after infection). For those diagnosed as HIV
positive with an HIV negative spouse or regular sexual
partner treatment is initiated on diagnosis, irrespective
of CD4 level, to assist in preventing transmission. There-
fore, costs of treatment (personal and national) could be
estimated in two ways:
1. Treatment Cost Scenario 1: Diagnosis at 2 years
following infection (no direct costs incurred), 3 yearsTable 3 Estimated numbers of HIV infections averted
among people who inject drugs
2005 2006 2007 2008 2009 2010 Total
Minimum infections averted 78 428 551 814 934 1177 3982
Maximum infections averted 148 817 1051 1554 1782 2246 7599
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and ART for 5 years (5 x USD1147.20/year). A total
of 10 year survival from infection: total cost
USD6,895.00 (USD861.90/person/year). This was
used for our study.
2. Treatment Cost Scenario 2: ART introduced on or
around diagnosis (after two years following
infection) with an average of 29 years survival: total
cost USD33,269.70 (29 x USD1147.20/person/year)
which will be the predominant treatment cost
scenario for the future.Figure 2 Ratio of investment in harm reduction as compared to
treatment costs.Calculation of annual and cumulative net benefit
The annual and cumulative net benefit of averting HIV
infections was calculated using the average HIV infec-
tions averted annually. This finding was then used to es-
timate the cost of treatment for this group based on the
annual costs of providing one person with treatment in
the two treatment scenarios (Table 4).
Table 4 shows that from 2006 to 2010 there were pro-
gressive and positive increases in net benefit of averting
HIV infections treated under Treatment Scenario 1 from
USD109,399 in 2006 to USD4,383,728 in 2010.
In 2010 the new national policy to provide early treat-
ment began implementation (Treatment Scenario 2) but
was not introduced to XUAR until the end of 2011. If
this policy had been introduced in 2010 in XUAR it can
be seen that the treatment costs saved would increase if
all HIV infections averted in 2010 (1712) were treated
under treatment scenario 2. The accrued net benefit or
return on investment for the five year period up to 2010
would be USD 4,872,212 which is an additional cost sav-
ing of USD488,484. This was calculated based on the
sum of the accrued costs of the two treatment scenarios
existing simultaneously in 2010. Therefore, the net bene-
fit is expected to rise significantly as people entering
the treatment programme are treated under treatment
scenario 2.
The calculation of costs saved in providing treatment
per dollar invested in harm reduction programmes
demonstrated progressive cost benefits over the periodble 4 Net benefit of providing harm reduction services from
B C






tal 3,207,661of study. This is shown in Figure 2 and was calculated
annually (Table 4, Column B: Column D) for Treatment
Scenario 1. This ratio increased from USD1 (invested in
harm reduction): USD1.21 (saved in treatment costs) in
2006 to USD1:USD8.22 in 2010.
In calculating this ratio for the first year (2010) of
Treatment Scenario 2 the ratio was 1:3.2. If treatment
Scenarios 1 and 2 were to exist together the cost
ratio for 2010 would be USD1:USD9. Therefore, the
return on investment will increase as survival rates
increase (with implementation of Treatment Scenario
2) assuming cost components remain relatively stable,
that HIV infections averted continue to increase and
incidence remains stable or decreases.
These results demonstrate the net and accumulating
benefit of investing in harm reduction programmes for
PWID in Urumqi. The return on investment has been
progressively increasing during the time period studied
and it is clear that these cost savings will continue to ac-
crue with the continued implementation of HIV preven-
tion interventions in the community that include harm
reduction programmes targeted at PWID.Discussion
This paper reports an assessment of return on investment
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2010 based on estimates of HIV infections averted. Over
this time period it is calculated that an average of 5790
(range 3982–7509) HIV infections have been averted
among PWID. It is possible that the provision of services
analysed in this paper specifically targeted at preventing
HIV transmission in this group have contributed, in part,
to this given that these are the only services available to
community based PWID in Urumqi. The costs of imple-
menting harm reduction programmes (MMT and NSP)
were calculated and the net amount saved in treatment
costs was estimated to be USD 4,383,728,212 accrued over
the period studied. The ratio of return on investment was
calculated and this increased annually from USD 1
(invested in harm reduction): USD1.21 (saved in treatment
costs for Treatment Scenario 1) in 2006 to USD 1: USD
8.22 in 2010.
Health economic analysis of the impact of harm reduc-
tion programmes in preventing HIV in China is limited. At
least one study, in Yunnan, has appeared in the literature
analyzing the benefit of NSP. [10] reported that between
2002 to 2008, the numbers of PWID protected from HIV
was estimated between 5200–7500 with cost savings of
USD 1.38-1.97 million per year. The results of this research
in Yunnan tend to support the findings of this research in
Urumqi even though the methodologies applied are
different.
The net benefits may be underestimated. Only direct
costs of providing harm reduction programmes and care
and treatment services have been taken into account. In-
direct benefits such as the ability of methadone users to
return to work and the social benefit of reported reduc-
tions in crime; and, long-term treatment for PLHIV con-
tributing to their capacity to participate fully in society
and generate income was not factored into this analysis.
Information on the actual situation is challenging to ob-
tain and this has limited the scope of this study. Informa-
tion was collated from various sources including
surveillance data, specific surveys and on-going studies
and research programmes being undertaken in Urumqi.
While the quality of data generated through national and
local data collection sources is improving, the reliability of
information from these sources is still indicative rather
than empirical.
Another limitation of the analysis is that BED HIV-
1 EIA Assay was used to estimate incidence. BED
HIV-1 EIA Assay testing is regarded as overestimat-
ing incidence [11,12]. There are few studies in XUAR
to verify the incidence rates reported however re-
search in Urumqi in 2003–2005 assessed sero-
incidence of HIV among 508 PWID living in the
community. This study found that there was a sero-
incidence of 8.8 per 100 person years [13]. Therefore,
at least for this period, the results of the BED HIV-1EIA Assay may be, at least, representative of the
actual situation.
Conclusion
Debate is on-going in China over the relative merits of
different forms of drug related harm reduction and HIV
prevention methodologies [14,15]. In many countries re-
ducing sharing of injecting equipment through the im-
plementation of NSP, drug substitution such as the
provision of methadone and buprenorphine and early
treatment for PLHIV to reduce risk of transmission co-
exist. However, in China due to limited political and so-
cial acceptance of drug use and a slow response to HIV
in the early stages of the epidemic, the burgeoning num-
ber of PLHIV requiring ART has led to current resource
allocations and priorities being focused on early treat-
ment. Advocacy for programmes targeted at harm re-
duction among active injecting drug users is challenging.
This is even more so in resource constrained environ-
ments and where there is social marginalization of the
target population. Against this background , the promo-
tion of research results that indicate the effectiveness of
interventions in harm reduction and HIV prevention
can support necessary policy shifts and the continued
scaling up of successful programmes.
It is recognized that the quality of the data has
required significant assumptions to be made in quantify-
ing net benefit of harm reduction programmes targeted
at PWID in Urumqi. Nonetheless, the analysis shows an
increasing and positive impact in relation to net benefits
(return on investment) of all HIV related programmes
that avert HIV transmission and, in particular, those pro-
grammes targeted at PWID. Continuation and scaling
up of these programmes is essential in continuing to
prevent HIV transmission.
Endnotes
aSource: Internal report of the Xinjiang Uighur Au-
tonomous Regional Center for Disease Control (2001).
bSource: “Supporting the Development of a Response to
HIV” Final Report for China-Australia Xinjiang HIV/
AIDS Prevention and Care Project (2009).
cSource: XUAR Center for Disease Control Report for
the National Research Programme 2010.
dSource: XUAR Public Security Bureau 20019.
eUSD 3,515,690 (4079 people x USD861.90/year) +
USD 1,964,058 (1712 people x USD 1147.20) =USD
5,499,748 less harm reduction costs in 2010 (USD
607,535) =USD 4,872,212.
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